Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations (Q35096909)

6 August 2017

title

Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations (English)

1 reference

6 August 2017

main subject

Clostridium difficile

0 references

Richard E Lee

0 references

Julian G Hurdle

1 reference

6 August 2017

Amy E Heathcott

series ordinal

1 reference

6 August 2017

Lei Yang

series ordinal

1 reference

6 August 2017

Bing Yan

series ordinal

1 reference

6 August 2017

language of work or name

English

0 references

publication date

31 May 2011

1 reference

Journal of Antimicrobial Chemotherapy

6 August 2017

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

1773-1776

1 reference

Emerging therapies forClostridium difficileinfections

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1.

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

Evaluation of analogs of reutericyclin as prospective candidates for treatment of staphylococcal skin infections

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

Characterization of reutericyclin produced by Lactobacillus reuteri LTH2584

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

N-substituted 3-acetyltetramic acid derivatives as antibacterial agents

9 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3133486

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21632577

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/JAC/DKR201

1 reference

6 August 2017

1 reference

6 August 2017

1 reference